{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', '14.5.', 'Records Retention', 'To enable evaluations and/or audits from regulatory authorities or the sponsor, the investigator', 'agrees to keep records, including the identity of all participating subjects (sufficient information', 'to link records, eCRFs, and medical/hospital records), all original signed ICFs, all original signed', 'assents (where applicable), all eCRFs, and detailed records of study drug accountability and', 'treatment disposition. The records should be retained by the investigator according to local', 'regulations or as specified in the Clinical Trial Agreement, whichever is longer.', 'If the investigator relocates, retires, or for any reason withdraws from the study, the study', 'records may be transferred to an acceptable designee, such as another investigator, another', \"institution, or to the sponsor. The investigator must obtain the sponsor's written permission\", 'before disposing of any records and must notify the sponsor before transferring any records to', 'another facility.', 'All correspondence related to records retention, destruction or transfer of study documents', 'should be sent directly to sponsor study personnel, copying the email archives@biocryst.com.', '14.6.', 'Confidentiality of Information and Data', \"The sponsor affirms the subject's right to protection against invasion of privacy and secure\", 'maintenance of the confidential nature of their personal data. Only a subject identification', 'number and subject identifiers permitted by local regulation will identify subject data retrieved', 'by the sponsor. However, in compliance with federal regulations, the sponsor requires the', \"investigator to permit the sponsor's representatives and, when necessary, representatives of the\", 'PMDA or other regulatory authorities to review and/or copy any medical records relevant to the', 'study, maintaining pseudo-anonymity.', 'All parties will abide by all applicable laws and regulations regarding subject privacy and', 'confidentiality. A valid authorization and consent must meet the specifications of the applicable', 'laws and regulations relating to such personal data and health information. It is the responsibility', 'of the investigator and institution to obtain such waiver/authorization in writing from the', 'appropriate individual.', '14.7.', 'Study Publication', 'All data generated from this study are the property of BioCryst and shall be held in strict', 'confidence along with all information furnished by BioCryst. Except as provided through prior', 'written agreement with BioCryst, independent analysis and/or publication of these data by the', 'investigator or any member of his/her staff is not permitted. Such consent will not be withheld', 'unreasonably. BioCryst is in agreement with the principle of full disclosure of clinical trial', 'results.', '105']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', '15.', 'REFERENCES', 'Aygoren-Pursun, E., A. Bygum, V. Grivcheva-Panovska, M. Magerl, J. Graff, U. C. Steiner,', 'O. Fain, A. Huissoon, T. Kinaciyan, H. Farkas, R. Lleonart, H. J. Longhurst, W. Rae, M.', 'Triggiani, W. Aberer, M. Cancian, A. Zanichelli, W. B. Smith, M. L. Baeza, A. Du-Thanh,', 'M. Gompels, T. Gonzalez-Quevedo, J. Greve, M. Guilarte, C. Katelaris, S. Dobo, M.', 'Cornpropst, D. Clemons, L. Fang, P. Collis, W. Sheridan, M. Maurer and M. Cicardi (2018).', '\"Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema.\" N Engl J Med', '379(4): 352-362.', 'Bork, K., J. Hardt and G. Witzke (2012). \"Fatal laryngeal attacks and mortality in hereditary', 'angioedema due to C1-INH deficiency.\" J Allergy Clin Immunol 130(3): 692-697.', 'Bork, K., G. Meng, P. Staubach and J. Hardt (2006). \"Hereditary angioedema: new findings', 'concerning symptoms, affected organs, and course.\" Am J Med 119(3): 267-274.', 'Bouillet, L., H. Longhurst, I. Boccon-Gibod, K. Bork, C. Bucher, A. Bygum, T. Caballero, C.', 'Drouet, H. Farkas, C. Massot, E. W. Nielsen, D. Ponard and M. Cicardi (2008). \"Disease', \"expression in women with hereditary angioedema.' Am J Obstet Gynecol 199(5): 484.e1-4\", 'Caballero, T., H. Farkas, L. Bouillet, T. Bowen, A. Gompel, C. Fagerberg, J. Bjokander, K.', 'Bork, A. Bygum, M. Cicardi, C. de Carolis, M. Frank, J. H. Gooi, H. Longhurst, I. Martinez-', 'Saguer, E. W. Nielsen, K. Obtulowitz, R. Perricone, N. Prior and C.I.D. W. Group (2012).', '\"International consensus and practical guidelines on the gynecologic and obstetric', 'management of female patients with hereditary angioedema caused by C1 inhibitor', \"deficiency.' J Allergy Clin Immunol 129(2): 308-320.\", 'Cicardi, M., K. Bork, T. Caballero, T. Craig, H. H. Li, H. Longhurst, A. Reshef, B. Zuraw', 'and Hawk (2012). \"Evidence-based recommendations for the therapeutic management of', 'angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International', \"Working Group.' Allergy 67(2): 147-157.\", 'Cornpropst, M., S. Dobo, J. Collier, A. Rose, R. Wilson, Y. S. Babu, P. Collis and W.', 'Sheridan (2016). \"BCX7353, a Potent Inhibitor of Plasma Kallikrein, Shows Sustained', 'Maximal Enzyme Inhibition When Dosed Orally Once Daily: Results from a Phase I Trial in', 'Healthy Subjects.\" Elsevier (AAAAI, Los Angeles).', 'Han, E. D., R. C. MacFarlane, A. N. Mulligan, J. Scafidi and A. E. Davis, 3rd (2002).', '\"Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin', 'type 2 receptor.\" J Clin Invest 109(8): 1057-1063.', 'Kaplan, A. P. (2010). \"Enzymatic pathways in the pathogenesis of hereditary angioedema:', 'the role of C1 inhibitor therapy.\" J Allergy Clin Immunol 126(5): 918-925.', 'Kaplan, A. P. and B. Ghebrehiwet (2010). \"The plasma bradykinin-forming pathways and its', 'interrelationships with complement.\" Mol Immunol 47(13): 2161-2169.', 'Longhurst, H. and M. Cicardi (2012). \"Hereditary angio-oedema.\" Lancet 379(9814): 474-', '481.', '106']\n\n###\n\n", "completion": "END"}